In Spring 2021, we were selected to be a part of a clinical trial that aims to measure the effectiveness of a new digital therapeutic called MODIA.
MODIA is an internet-based platform designed to deliver high quality psychotherapy by utilizing artificial intelligence technology. We know through prior research (and clinical practice) that medications for OUD are much more helpful when combined with psychosocial support; this makes MODIA the perfect partner for MAT treatment such as buprenorphine-naloxone (Suboxone, Zubsolv).
This study will compare two groups of subjects: those who receive buprenorphine-naloxone treatment and those who receive treatment as usual plus use of MODIA. We will follow our subjects weekly over the course of six months and will collect information about craving and drug use, as well as objective data such as urine drug screen results. The treatment will be provided at no cost to the subject, and subjects will be compensated for their time at the conclusion of each study visit.
We are currently in the enrollment phase. If you think you may be interested in participating and would like to see if you qualify, please call our Clinical Research Coordinator (Lauren) at (484)351-8031.
The learn more about MODIA and the study’s design, click the button below.
Are you looking for addiction treatment?
The Institute of Addiction Medicine is a sister organization to the Volpicelli Center for addiction treatment—a premier outpatient addiction treatment center in Pennsylvania.
Get updates on training options and news from the Institute of Addiction Medicine